This is achieved by using a specific sugar compound during the infection, so-called 2-Deoxy-D-glucose (2-DG). This sugar molecule differs from glucose in that it lacks a hydroxyl group, consisting of one hydrogen atom and one oxygen atom. Administering 2-DG, which serves to inhibit glycolysis, causes increased production of interleukin-12 (IL-12), a pro-inflammatory cytokine, while suppressing the production of interleukin-10, an anti-inflammatory cytokine.
One of the main functions of IL-12 is to trigger a specific T-cell immune response, which is part of the cellular immune response, to specifically boost the defence mechanisms that serve to eliminate intracellular pathogens (such as listeria, for example).
"The administration of 2-DG apparently changes the nature of the immune response and hence also the intensity of the inflammatory process," explains Gerhard Zlabinger, MedUni Vienna immunologist. "Inflammation is modulated so that the immune system is once again able to manage the situation itself, without allowing the infection to have a lethal outcome. It is as if we are pressing the reset button, thereby preventing excessive inflammatory responses."
The underlying mechanism is not yet known. According to Johannes Kovarik, lead author of the study, the expression of IL-12 , which can be formed by two separate chains (p35 and/or p40), probably plays a role. Following administration of 2-DG, only p40 is upregulated, while no p35 is produced. This modified cytokine profile (there is also a simultaneous increase in IL-23 expression) could subsequently bring about modified recruitment of immune cells and hence have a decisive influence upon the intensity of the immune response.
"Our study is an excellent example of the importance of the immune metabolism, that is to say the modified metabolism of essential nutrients by activated immune system cells," explains MFPL Group Leader Thomas Decker. "We were amazed by the extent to which mice became resistant to bacterial infections due to inhibition of the glucose metabolism. This metabolic reversal creates a push-pull effect: increased production of activating mediators with simultaneous inhibition of immunosuppressive mediators."
Manipulation of the sugar metabolism and associated modulation of the immune system could open up new options for treating specific infectious and also autoimmune diseases in the future. Further research work will, of course, be required for this – some projects are already being started at MedUni Vienna's Institute of Immunology.
Service: PLOS ONE
„Fasting metabolism modulates the interleukin-12/interleukin-10 cytokine axis.“
J.J. Kovarik, E. Kernbauer, M.A. Hölzl, J. Hofer, G.A. Gualdoni, K.G. Schmetterer, F. Miftari, Y. Sobanov, A. Meshcheryakova, D. Mechtcheriakova, N. Witzeneder, G. Greiner, A. Ohradanova-Repic, P. Waidhofer-Söllner, M.D. Säemann, T. Decker, G.J. Zlabinger.
Medical University Vienna
Mag. Johannes Angerer
Head of Corporate Communications and press officer
Tel: +43 (0)1 40160 - 11 501
Mobil: +43 664 800 16 11 501